Nymox Pharmaceutical Corporation (NYMXF)
OTCMKTS · Delayed Price · Currency is USD
0.0320
-0.0036 (-10.11%)
Oct 1, 2026, 4:00 PM EST
Nymox Pharmaceutical Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.01 | 0.07 | 0.07 | 1.4 | 0.83 |
Cash & Short-Term Investments | 0.01 | 0.07 | 0.07 | 1.4 | 0.83 |
Cash Growth | -91.89% | 5.71% | -95.01% | 69.04% | -77.02% |
Other Receivables | 0.02 | 0.03 | 0.01 | 0.01 | 0.01 |
Receivables | 0.02 | 0.03 | 0.01 | 0.01 | 0.01 |
Inventory | - | - | - | - | 0.03 |
Prepaid Expenses | 0.01 | 0.02 | 0.02 | 0.02 | 0.13 |
Other Current Assets | 0.54 | 0.54 | 0.53 | 0.03 | 0.03 |
Total Current Assets | 0.58 | 0.65 | 0.63 | 1.46 | 1.04 |
Property, Plant & Equipment | 0 | 0 | 0 | 0.17 | 0.41 |
Total Assets | 0.58 | 0.65 | 0.63 | 1.63 | 1.44 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.03 | 3.87 | 3.02 | 1.7 | 1.27 |
Accrued Expenses | 0.03 | 0.03 | 0.03 | 0.24 | 0.29 |
Short-Term Debt | 5.83 | 3.53 | 0.75 | - | - |
Current Portion of Leases | - | - | - | 0.17 | 0.23 |
Total Current Liabilities | 9.88 | 7.43 | 3.8 | 2.11 | 1.79 |
Long-Term Leases | - | - | - | - | 0.16 |
Total Liabilities | 9.88 | 7.43 | 3.8 | 2.11 | 1.95 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 173.88 | 173.88 | 173.82 | 171.67 | 165.06 |
Additional Paid-In Capital | 33.29 | 28.01 | 27.78 | 26.99 | 27.58 |
Retained Earnings | -216.75 | -212.47 | -207.98 | -199.14 | -192.56 |
Comprehensive Income & Other | 0.27 | 3.81 | 3.21 | - | -0.59 |
Shareholders' Equity | -9.31 | -6.78 | -3.17 | -0.48 | -0.51 |
Total Liabilities & Equity | 0.58 | 0.65 | 0.63 | 1.63 | 1.44 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 5.83 | 3.53 | 0.75 | 0.17 | 0.39 |
Net Cash (Debt) | -5.82 | -3.46 | -0.68 | 1.23 | 0.44 |
Net Cash Growth | - | - | - | 180.18% | -86.22% |
Net Cash Per Share | -0.06 | -0.04 | -0.01 | 0.01 | 0.01 |
Filing Date Shares Outstanding | 105.04 | 94.54 | 93.54 | 91.27 | 90.28 |
Total Common Shares Outstanding | 102.04 | 94.54 | 93.54 | 90.52 | 85.55 |
Working Capital | -9.31 | -6.78 | -3.18 | -0.65 | -0.75 |
Book Value Per Share | -0.09 | -0.07 | -0.03 | -0.01 | -0.01 |
Tangible Book Value | -9.31 | -6.78 | -3.17 | -0.48 | -0.51 |
Tangible Book Value Per Share | -0.09 | -0.07 | -0.03 | -0.01 | -0.01 |
Machinery | 0.6 | 0.6 | 0.6 | 0.59 | 0.59 |